West Pharmaceutical Services said consolidated net sales for the 3 months ended September 30, 2025 increased by $57.7 million, or 7.7%, compared with the same period in the prior year. Excluding foreign currency translation effects, consolidated net sales increased by $37.6 million, or 5.0%.

10-QQuarterly reportFiled Oct 23, 2025Period of report Sep 30, 2025Summary published (UTC) Oct 10, 2026

Key points

AI summary

West Pharmaceutical Services said consolidated net sales for the 3 months ended September 30, 2025 increased by $57.7 million, or 7.7%, compared with the same period in the prior year. Excluding foreign currency translation effects, consolidated net sales increased by $37.6 million, or 5.0%.
The company said Proprietary Products net sales for the 3 months increased by $46.1 million, or 7.7%, and excluding foreign currency translation effects increased by 5.1%. It cited increases in sales of Westar®, Envision® and NovaBrand products, partially offset by approximately $19 million in customer incentives received in connection with volumes achieved in the prior-year period that were not repeated.
The company said consolidated gross profit for the 3 months ended September increased by $29.6 million, or 11.2%, as compared to the same period in the prior year, and consolidated gross profit margin increased by 1.2 margin points. This included a favorable foreign currency translation impact of $8.6 million.
The company said as of September 30, 2025 it had no borrowings outstanding under its revolving credit facility and $497.7 million in available capacity. It also said it repurchased 552,593 shares for $134.0 million, or $242.55 per share, during the 9 months.

Key figures

Quarter ended September 30, 2025

Revenue: $805M
Operating income: $168M
Net income: $140M
EPS: $1.92
Gross profit: $294M

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Consolidated Net Sales Increased $57.7 million for Q3 2025

West Pharmaceutical Services said consolidated net sales for the 3 months ended September 30, 2025 increased by $57.7 million, or 7.7%, compared with the same period in the prior year. Excluding foreign currency translation effects, consolidated net sales increased by $37.6 million, or 5.0%.

Source · Based on the MD&A text of the filing

Proprietary Products Net Sales and Non-Repetition of Prior-Year Incentives

The company said Proprietary Products net sales for the 3 months increased by $46.1 million, or 7.7%, and excluding foreign currency translation effects increased by 5.1%. It cited increases in sales of Westar®, Envision® and NovaBrand products, partially offset by approximately $19 million in customer incentives received in connection with volumes achieved in the prior-year period that were not repeated.

Source · Based on the MD&A text of the filing

Consolidated Gross Profit and Gross Profit Margin Changes for Q3

The company said consolidated gross profit for the 3 months ended September increased by $29.6 million, or 11.2%, as compared to the same period in the prior year, and consolidated gross profit margin increased by 1.2 margin points. This included a favorable foreign currency translation impact of $8.6 million.

Source · Based on the MD&A text of the filing

Revolving Credit Facility Available Capacity and Share Repurchases

The company said as of September 30, 2025 it had no borrowings outstanding under its revolving credit facility and $497.7 million in available capacity. It also said it repurchased 552,593 shares for $134.0 million, or $242.55 per share, during the 9 months.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.